Concepedia

Timothy Nicholas

TN

Statistics

Publications

21

Citations

644

H-Index

14

Active since

1995

Affiliations

Pfizer (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Critical Path Institute

Parkinson's UK

UCB Pharma (Belgium)

Timothy Nicholas is an author at Pfizer (United States) specializing in neurodegenerative diseases, pharmacology, and neuroscience.

Publications per year

1995–2025

21

Publications

21

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

Kaori Ito, Brian Corrigan, Qinying Zhao et al. · Alzheimer s & Dementia · 2010 · 140 citations

, , +17

A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease

Elias Schwam, Timothy Nicholas, Robert Chew et al. · Current Alzheimer Research · 2014 · 79 citations

, , +17

Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.

David Rush, W J Stelmach, Tom Young et al. · PubMed · 1995 · 74 citations

, , +16

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

Daniela J. Conrado, Timothy Nicholas, Kuenhi Tsai et al. · Clinical and Translational Science · 2017 · 46 citations · Full text

, , +16

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

Diane Stephenson, Jesse M. Cedarbaum, Maria Tome et al. · Journal of Parkinson s Disease · 2019 · 44 citations · Full text

, , +17

1–5 of 21